Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes

Leukemia and Lymphoma

Volumn 54, Issue 1, 2013, Pages 28-35

  Churpek, Jane E ^a   Lorenz, Rachelle ^a   Nedumgottil, Siya ^a   Onel, Kenan ^a   Olopade, Olufunmilayo I ^a   Sorrell, April ^b   Owen, Carolyn J ^c   Bertuch, Alison A ^d   Godley, Lucy A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b City of Hope ^*  (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CEBPA; GATA2; Leukemia; MDS; Predisposition; RUNX1

Indexed keywords

ANTINEOPLASTIC AGENT; HLA ANTIGEN; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE ASSOCIATION; FAMILIAL CANCER; FAMILIAL PLATELET DISORDER; FAMILY HISTORY; FERTILIZATION IN VITRO; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; HUMAN; LEUKOPLAKIA; LUNG FIBROSIS; MONOCYTOPENIA; MYELODYSPLASTIC SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGENY; PSYCHOSOCIAL CARE; REVIEW; RISK ASSESSMENT; SKIN PIGMENTATION; TELOMERE; THROMBOCYTE DISORDER;

DISEASE SUSCEPTIBILITY; FAMILY; GENETIC COUNSELING; GENETIC TESTING; HUMANS; LEUKEMIA; MYELODYSPLASTIC SYNDROMES; PRACTICE GUIDELINES AS TOPIC;

EID: 84870938434     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.701738     Document Type: Review

References (39)

1. Godley LA, Larson RA. Th erapy-related myeloid leukemia. Semin Oncol 2008 ; 35: 418-429.
2. Gunz FW, Gunz JP, Veale AM, et al. Familial leukaemia: A study of 909 families. Scand J Haematol 1975 ; 15: 117-131.
3. Horwitz M. The genetics of familial leukemia. Leukemia 1997 ; 11: 1347-1359. (Pubitemid 27387314)
4. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: Implications for mechanisms of pathogenesis. Blood 2002 ; 99: 1364-1372. (Pubitemid 34547093)
5. Song WJ, Sullivan MG, Legare RD, et al. Haploinsuffi ciency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166- 175. (Pubitemid 29455388)
6. Smith ML, Cavenagh JD, Lister TA, et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 2004; 351: 2403- 2407.
7. Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011 ; 43: 1012-1017.
8. Ripperger T, Tauscher M, Haase D, et al. Managing individuals with propensity to myeloid malignancies due to germline RUNX1 defi ciency. Haematologica 2011; 96: 1892- 1894.
9. Dokal I, Vulliamy T. Inherited bone marrow failure syndromes. Haematologica 2010; 95: 1236- 1240.
10. Alter BP. Inherited bone marrow failure syndromes. In: Nathan DG, Orkin SH, Look AT, et al., editors. Nathan and Oski' s hematology of infancy and childhood. 6th ed. Philadelphia, PA: WB Saunders Inc.; 2003. pp 280-365.
11. Eiler ME, Frohnmayer D, Frohnmayer L, et al., editors. Fanconi anemia guidelines for diagnosis and management. 3rd ed. Eugene, OR: Fanconi Anemia Research Fund, Inc.; 2008.
12. Dror Y, Donadieu J, Koglmeier J, et al. Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. Ann NY Acad Sci 2011 ; 1242: 40-55.
13. Savage SA, Dokal I, Armanios M, et al. Dyskeratosis congenita: The fi rst NIH clinical research workshop. Pediatr Blood Cancer 2009 ; 53: 520-523.
14. Connelly JA, Choi SW, Levine JE. Hematopoietic stem cell transplantation for severe congenital neutropenia. Curr Opin Hematol 2012 ; 19: 44-51.
15. Fogarty PF, Yamaguchi H, Wiestner A, et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 2003 ; 362: 1628-1630. (Pubitemid 37443532)
16. Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia-a review. Br J Haematol 2008 ; 140: 123-132. (Pubitemid 350265048)
17. Gerrard JM, Israels ED, Bishop AJ, et al. Inherited platelet-storage pool defi ciency associated with a high incidence of acute myeloid leukaemia. Br J Haematol 1991 ; 79: 246-255.
18. Sun L, Mao G, Rao AK. Association of CBFA2 mutation with decreased platelet PKC-theta and impaired receptor-mediated activation of GPIIb-IIIa and pleckstrin phosphorylation: Proteins regulated by CBFA2 play a role in GPIIb-IIIa activation. Blood 2004 ; 103: 948-954. (Pubitemid 38129555)
19. Liew E, Owen C. Familial myelodysplastic syndromes: A review of the literature. Haematologica 2011 ; 96: 1536-1542.
20. Stelljes M, Corbacioglu A, Schlenk RF, et al. Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAATenhancer-binding protein alpha from hematopoietic cells in a family with AML. Leukemia 2011 ; 25: 1209-1210.
21. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: Further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011 ; 117: 2469-2475.
22. D ickinson RE, G riffi n H, Bigley V, et al. Exome sequencing identifi es GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid defi ciency. Blood 2011 ; 118: 2656-2658.
23. H su AP, S ampaio EP, K han J, et al. M utations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011 ; 118: 2653-2655.
24. Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011; 43: 929- 931.
25. C alvo KR, V inh DC, M aric I, et al. M yelodysplasia in autosomal dominant and sporadic monocytopenia immunodefi ciency syndrome: Diagnostic features and clinical implications. Haematologica 2011 ; 96: 1221-1225.
26. Alter BP, Giri N, Savage SA, et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010 ; 150: 179-188.
27. Savage SA, Bertuch AA. The genetics and clinical manifestations of telomere biology disorders. Genet Med 2010 ; 12: 753-764.
28. K irwan M, V ulliamy T, M arrone A, et al. D efi ning the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat 2009 ; 30: 1567-1573.
29. Nelson ND, Bertuch AA. Dyskeratosis congenita as a disorder of telomere maintenance. Mutat Res 2012; 730: 43- 51.
30. Tegg EM, Th omson RJ, Stankovich JM, et al. Anticipation in familial hematologic malignancies. Blood 2011 ; 117: 1308-1310.
31. Horwitz M, Goode EL, Jarvik GP. Anticipation in familial leukemia. Am J Hum Genet 1996 ; 59: 990-998. (Pubitemid 26346337)
32. Lynch HT, Follett KL, Lynch PM, et al. Family history in an oncology clinic. Implications for cancer genetics. JAMA 1979; 242: 1268- 1272. (Pubitemid 10244424)
33. Owen CJ, Toze CL, Koochin A, et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 2008 ; 112: 4639-4645.
34. P abst T, E yholzer M, H aefl iger S, et al. S omatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 2008 ; 26: 5088-5093.
35. Buijs A, Poddighe P, van Wijk R, et al. A novel CBFA2 singlenucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood 2001; 98: 2856- 2858.
36. Clancy T. A clinical perspective on ethical arguments around prenatal diagnosis and preimplantation genetic diagnosis for later onset inherited cancer predispositions. Fam Cancer 2010 ; 9: 9-14.
37. National Society of Genetic Counselors. Position statement on prenatal and childhood testing for adult-onset disorders [Internet]. Available from: Http://www.nsgc.org/Media/PositionStatements/tabid/330/Default. aspx#PrenatalChildTestingAdultOnset [38] NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: Breast and ovarian. v.1. 2011 [Internet]. Available from: Http://www.nccn.org/professionals/physician-gls/f- guidelines.asp [39] Spits C, De Rycke M, Van Ranst N, et al. Preimplantation genetic diagnosis for cancer predisposition syndromes. Prenat Diagn 2007; 27: 447-456.
38. D ewanwala A, C hittenden A, R osenblatt M, et al. A ttitudes toward childbearing and prenatal testing in individuals undergoing genetic testing for Lynch syndrome. Fam Cancer 2011; 10: 549- 556.
39. Raya A, Rodriguez-Piza I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009 ; 460: 53-59.